logo
  

Novartis To Petition U.S. Supreme Court To Uphold Patent Validity Of Gilenya Dosing Regimen

Swiss drug major Novartis AG (NVS) announced Wednesday it plans to file a petition to the U.S. Supreme Court to uphold validity of the Gilenya (fingolimod) dosing regimen patent.

The decision comes as the U.S. Court of Appeals for the Federal Circuit or CAFC has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya.

Novartis said it plans to seek further review of the CAFC's decision with the US Supreme Court.

The U.S. District Court for the District of Delaware in August 2020 issued a favorable decision and a permanent injunction was granted against HEC Pharma until the expiration of the '405 patent in December 2027, including pediatric exclusivity.

HEC Pharma was the only remaining Abbreviated New Drug Application or ANDA filer challenging this patent.

In January 2022, CAFC's three-judge panel issued a decision upholding the validity of the dosing regimen patent. HEC subsequently filed a petition for rehearing with the CAFC. In June 2022, a modified panel from the CAFC issued a reversal of its previous decision and found the patent invalid.

Novartis entered into settlement agreements with a number of ANDA filers earlier, under which those ANDA filers would have been able to launch a generic version of Gilenya, if approved by FDA, on an agreed upon date that is prior to the expiration of the dosing regimen patent, or earlier than the agreed upon date under certain circumstances.

With the latest decision, HEC and other ANDA filers with FDA approval will potentially be able to launch a generic version of 0.5mg Gilenya imminently, pending any other judicial actions.

Novartis said it intends to vigorously defend the validity of the patent and is considering all available options, including current plans to seek review of this decision by petition to the US Supreme Court. The process is likely to take several months to determine if the petition will be granted.

Regarding the financial impact, Novartis now said, "Should generics launch in the US, we expect FY 2022 sales to be negatively impacted by USD 0.3bn. With regard to 2022 Full Year Guidance for Group sales and core operating income growth, we continue to expect both in the mid-single digit range, in constant currencies."

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
Follow RTT